Pregabalin Dosing and Safety in Severe Renal Impairment (eGFR < 15 mL/min)

FDA‑Recommended Dosing Algorithm

Evidence: FDA labeling (high‑level regulatory guidance).

Practical Dose Reduction Strategy

Evidence: FDA labeling and pharmacokinetic rationale (moderate‑level guidance).

Monitoring and Follow‑Up

Evidence: KDOQI clinical practice guideline (strong guideline recommendation).

Neurological Toxicity Profile in Severe CKD

Evidence: Observational data reported in the American Journal of Kidney Diseases (moderate evidence).

Safety Considerations Relative to Other CNS Depressants

Evidence: KDOQI guideline and FDA labeling (strong guideline recommendation).

All facts are derived from cited sources and presented in English for clinical guidance.